Endoscopic Sleeve Gastroplasty on Obesity-Related Comorbidities

Endoscopic Sleeve Gastroplasty (ESG) has shown significant promise in managing obesity-related comorbidities, as evidenced by a prospective 5-year study. Here are the key findings related to its impact:

1. Weight Loss

• Patients undergoing ESG achieved an average weight loss of 11.8% over a 5-year period. This weight reduction is considered clinically significant and sustainable for long-term health benefits.

2. Improvement in Obesity-Related Comorbidities

ESG demonstrated substantial improvements in several obesity-related conditions:

• Hypertension: Sustained reductions in systolic blood pressure were observed, indicating better control of high blood pressure.
• Dyslipidemia: LDL cholesterol levels were significantly reduced, improving lipid profiles and reducing cardiovascular risks.
• Type 2 Diabetes: HbA1c levels, a marker of long-term blood sugar control, were significantly lowered, indicating better glycemic management.
• Metabolic-Associated Steatotic Liver Disease (MASLD): ESG improved liver function markers, suggesting a positive impact on liver health and a reduction in fatty liver disease progression.

3. Reduced Medication Dependence

• Patients experienced a decreased need for medications to manage their comorbidities, highlighting the metabolic benefits of ESG beyond weight loss.

4. Minimally Invasive and Long-Term Efficacy

• ESG is a minimally invasive procedure, making it an attractive alternative to more invasive bariatric surgeries.
• The 5-year follow-up data supports its long-term efficacy for both weight reduction and metabolic improvements.

Conclusion

The study underscores ESG as an effective therapeutic option for addressing both obesity and its associated comorbidities. By improving key metabolic markers, reducing medication reliance, and achieving sustained weight loss, ESG offers a comprehensive and minimally invasive approach to managing obesity and its related health challenges.